Larimar: Q1 Earnings Snapshot
FacebookTwitterEmail
BALA CYNWYD, Pa. (AP) Larimar Therapeutics, Inc. (LRMR) on Monday reported a loss of $12.1 million in its first quarter.
On a per-share basis, the Bala Cynwyd, Pennsylvania-based company said it had a loss of 76 cents.
Larimar shares have declined 39% since the beginning of the year. In the final minutes of trading on Monday, shares hit $13.12, an increase of 26% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LRMR at https://www.zacks.com/ap/LRMR Top Picks In Shopping
Published: Mar 04, 2021
Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich s
ataxia (FA) patients
Cash and investments of $92.6 million as of December 31, 2020
BALA CYNWYD, Pa., March 04, 2021 (GLOBE NEWSWIRE) Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2020 operating and financial results.
“2020 was a transformational year for Larimar as we entered the public market, built a strong institutional shareholder base, and reported initial clinical findings in our lead Friedreich’s ataxia (FA) program,” said Carole Ben-Maimon
Larimar: Q4 Earnings Snapshot sfgate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfgate.com Daily Mail and Mail on Sunday newspapers.
Annual Changes To The Nasdaq Biotechnology Index Date
11/12/2020
Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
The following 100 securities will be added to the Index:
EXCHANGE